IXX Jornadas del Comité de Graduados de la Sociedad Argentina de Diabetes. Tema: “Diabetes y órganos no clásicos”. Mesa 3: Complicaciones de la diabetes en piel, músculo, hueso y articulaciones
DOI:
https://doi.org/10.47196/diab.v57i1.667Palabras clave:
dermopatía diabética, sarcopenia, amiotrofia diabética, hiperostosis esquelética idiopática difusa, capsulitis adhesivaResumen
Las complicaciones en piel, músculo, hueso y articulaciones asociadas a la diabetes mellitus son frecuentes, múltiples y no siempre diagnosticadas en etapas tempranas. En esta revisión se evaluarán las características que consideramos de mayor relevancia.
Citas
I. Bustan RS, Wasim D, Yderstræde KB, Bygum A. Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state. A systematic review. Dan Med J 2017 Jan;64(1). Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28007053.
II. Mistry BD, Alavi A, Ali S, Mistry N. A systematic review of the relationship between glycemic control and necrobiosis lipoidica diabeticorum in patients with diabetes mellitus. International Journal of Dermatology 2017;56:1319-27. doi: 10.1111/ijd.13610.
III. Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. Clin Diabetes 2015 Jan;33(1):40-8.
IV. Svoboda SA, Shields BE. Cutaneous manifestations of nutritional excess: pathophysiologic effects of hyperglycemia and hyperinsulinemia on the skin. Cutis 2021;107. doi: 10.12788/cutis.0173.
V. Lima AL, Illing T, Schliemann S, Elsner P. Cutaneous manifestations of diabetes mellitus: a review. Am J Clin Dermatol 2017 Aug;18(4):541-53.
VI. Lepe K, Riley CA, Salazar FJ. Necrobiosis lipoidica. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
VII. Erfurt-Berge C, Heusinger V, Reinboldt-Jockenhöfer F, Dissemond J, Renner R. Comorbidity and therapeutic approaches in patients with necrobiosis lipodica. Dermatology 2021;1-8. doi: 10.1159/000514687.
VIII. Hines A, Alavi A, Davis MDP. Cutaneous manifestations of diabetes. Med Clin North Am 2021 Jul;105(4):681-97.
IX. Crizón-Díaz DP, Morales-Cardona CA. Manifestaciones dermatológicas de la diabetes: clasificación y diagnóstico. Iatreia 2020;33:239-50. doi: 10.17533/udea.iatreia.58.
X. Parra CA. Transepithelial elimination in necrobiosis lipoidica. British Journal of Dermatology 1977;96:83-6. doi: 10.1111/j.1365-2133.1977.tb05191.x.
XI. Pal RS, Wal P, Pal Y, Wal A. Recent insights on diabetic dermopathy. The Open Dermatology Journal 2019;13:8-12. doi: 10.2174/1874372201913010008.
XII. Karadag AS, Ozlu E, Lavery MJ. Cutaneous manifestations of diabetes mellitus and the metabolic syndrome. Clin Dermatol 2018 Jan;36(1):89-93.
XIII. Ayhan E, Arac E. Is diabetic dermopathy related with microangiopathic complications? Ann Med Res 2019;26(8):1445-8.
XIV. Naik PP, Farrukh SN. Clinical significance of diabetic dermatopathy. Diabetes Metab Syndr Obes 2020 Dec 8;13:4823-7.
XV. Gravani A, Gaitanis G, Tsironi T, Tigas S, Bassukas ID. Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors. J Eur Acad Dermatol Venereol 2018 Dec;32(12):e438-9.
XVI. Fania L, Di Zenzo G, Didona B, Pilla MA, Sobrino L, Panebianco A, et al. Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade. J Eur Acad Dermatol Venereol 2018 Apr;32(4):e153-4.
XVII. Ran M, Wang Y. Generalized granuloma annulare associated with diabetes mellitus. N Engl J Med 2016 Sep 8;375(10):e21.
XVIII. Almazan E, Roh YS, Belzberg M, Qin CX, Williams K, Choi J, et al. Comorbidities associated with granuloma annulare. A cross-sectional, case-control study. Medicines (Basel) 2020 Aug 28;7(9). doi. 10.3390/medicines7090053.
XIX. Barbieri JS, Rosenbach M, Rodríguez O, Margolis DJ. Association of granuloma annulare with type 2 diabetes, hyperlipidemia, autoimmune disorders, and hematologic malignant neoplasms. JAMA Dermatol 2021 Jul 1;157(7):817-23.
XX. Agrawal P, Pursnani N, Jose R, Farooqui M. Granuloma annulare: a rare dermatological manifestation of diabetes mellitus. J Family Med Prim Care 2019 Oct;8(10):3419-21.
XXI. Wang J, Khachemoune A. Granuloma annulare: a focused review of therapeutic options. Am J Clin Dermatol 2018 Jun;19(3):333-44.
XXII. González L, Peñaranda E. Acantosis nigricans: dos presentaciones de una misma enfermedad. Rev Asoc Colomb Dermatol 2010;18: 248-50.23. Phiske MM. An approach to acanthosis nigricans. Indian Dermatol Online J 2014 Jul;5(3):239-49.
XXIII. Phiske MM. An approach to acanthosis nigricans. Indian Dermatol Online J 2014 Jul;5(3):239-49.
XXIV. Das A, Datta D, Kassir M, Wollina U, Galadari H, Lotti T, et al. Acanthosis nigricans: a review. J Cosmet Dermatol 2020 Aug;19(8):1857-65.
XXV. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J 2008 Sep 15;14(9):2.
XXVI. Barbato MT, Criado PR, da Silva AK, Averbeck E, Guerine MB, de Sá NB. Association of acanthosis nigricans and skin tags with insulin resistance. Anais Brasileiros de Dermatologia 2012;87:97-104. doi: 10.1590/s0365-05962012000100012.
XXVII. Generator M. Vista de Cuarta Encuesta nacional de factores de riesgo. Visión nefrológica de los principales resultados. Disponible en: www.revistarenal.org.ar/index.php/rndt/article/view/498/964.
XXVIII. Marmur ES, Pasternack FR, Varghese MC. Dermatological complications of diabetes mellitus. Allergy to insulin and oral Agents. Principles of Diabetes Mellitus 2004; 473-490.
XXIX. Voore P, Odigwe C, Mirrakhimov AE, Rifai D, Iroegbu NA. DRESS syndrome following metformin administration: a case report and review of the literatura. American Journal of Therapeutics 2016;23: e1970-3. doi: 10.1097/mjt.0000000000000292.
XXX. Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015 Aug 12;11(4):840-8.
XXXI. Patel PM, Jones VA, Kridin K, Amber KT. The role of dipeptidyl Peptidase‐4 in cutaneous disease. Experimental Dermatology 2021;30:304-18. doi: 10.1111/exd.14228.
XXXII. Yang W, Cai X, Zhang S, Han X, Ji L. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events. A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2021 Mar;37(3):e3391.
XXXIII. Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, et al. Adverse events with sodium-glucose co-transporter-2 inhibitors. A global analysis of international spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases 2017;27:1098-107. doi: 10.1016/j.numecd.2017.10.008.
XXXIV. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013 Sep;27(5):479-84.
XXXV. Jedlowski PM, Te CH, Segal RJ, Fazel MT. Cutaneous adverse effects of diabetes mellitus medications and medical devices: a review. Am J Clin Dermatol 2019 Feb;20(1):97-114.
XXXVI. Betarbet U, Blalock TW. Keloids: a review of etiology, prevention, and treatment. J Clin Aesthet Dermatol 2020 Feb;13(2):33-43.
XXXVII. Sabban EN, Margossian M. Cutaneous manifestations induced by antidiabetic treatment. Cutaneous Manifestations of Diabetes 2018:137-137. doi: 10.5005/jp/books/13050_10.
XXXVIII. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018 Apr;138:271-81.
XXXIX. Briggs AM, Woolf AD, Dreinhöfer K, Homb N, Hoy DG, Kopansky-Giles D, et al. Reducing the global burden of musculoskeletal conditions. Bull World Health Organ 2018 May 1;96(5):366-8.
XL. St-Onge MP, Gallagher D. Body composition changes with aging: the cause or the result of alterations in metabolic rate and macronutrient oxidation? Nutrition 2010 Feb;26(2):152-5.
XLI. Hong S, Chang Y, Jung HS, Yun KE, Shin H, Ryu S. Relative muscle mass and the risk of incident type 2 diabetes: A cohort study. PLoS One 2017 Nov 30;12(11):e0188650.
XLII. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005 Mar;81(3):555-63.
XLIII. Mayhew AJ, Amog K, Phillips S, Parise G. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses. Age Ageing 2019;48(1):48-56.
XLIV. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord 2017 May 16;16:21.
XLV. Son JW, Lee SS, Kim SR, Yoo SJ, Cha BY, Son HY, et al. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. Diabetologia 2017 May;60(5):865-72.
XLVI. Morley JE, Malmstrom TK, Rodríguez-Mañas L, Sinclair AJ. Frailty, sarcopenia and diabetes. Journal of the American Medical Directors Association 2014;15:853-9. doi: 10.1016/j.jamda.2014.10.001.
XLVII. La Colla A, Pronsato L, Milanesi L, Vasconsuelo A. 17β-Estradiol and testosterone in sarcopenia: role of satellite cells. Ageing Res Rev 2015 Nov;24(Pt B):166-77.
XLVIII. Tamaki T, Hirata M, Uchiyama Y. Qualitative alteration of peripheral motor system begins prior to appearance of typical sarcopenia syndrome in middle-aged rats. Front Aging Neurosci 2014 Oct 30;6:296.
XLIX. Russell ST, Rajani S, Dhadda RS, Tisdale MJ. Mechanism of induction of muscle protein loss by hyperglycaemia. Exp Cell Res 2009 Jan 1;315(1):16-25.
L. de Rekeneire N, Peila R, Ding J, Colbert LH, Visser M, Shorr RI, et al. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 2006 Aug;29(8):1902-8.
LI. Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes 2019 Jul 8;12:1057-72.
LII. Rendón-Rodríguez R. El papel de la nutrición en la prevención y manejo de la sarcopenia en el adulto mayor. Nutrición Clínica en Medicina 2018;12(1):23-36.
LIII. Casals-Vázquez C, Suárez-Cadenas E, Carvajal FME, Trujillo MPA, Arcos MJ, Sáchez MÁV. Relación entre calidad de vida, actividad física, alimentación y control glucémico con la sarcopenia de adultos mayores con diabetes mellitus tipo 2. Nutrición Hospitalaria 2017. doi: 10.20960/nh.1070.
LIV. Goyal R, Faizy AF, Siddiqui SS, Singhai M. Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects. N Am J Med Sci 2012 Apr;4(4):180-4.
LV. King DE, Mainous AG, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003 May;26(5):1535-9.
LVI. Vozarova B, Weyer C, Hanson K, Antonio Tataranni P, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obesity Research 2001;9:414-7. doi: 10.1038/oby.2001.54.
LVII. Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress. A concise review. Saudi Pharmaceutical Journal 2016 Sep 1;24(5):547-53.
LVIII. Miljkovic I, Kuipers AL, Cauley JA, Prasad T, Lee CG, Ensrud KE, et al. Greater skeletal muscle fat infiltration is associated with higher all-cause and cardiovascular mortality in older men. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2015;70:1133-40. doi :10.1093/gerona/glv027.
LIX. Lee J, Hong YP, Shin HJ, Lee W. Associations of sarcopenia and sarcopenic obesity with metabolic syndrome considering both muscle mass and muscle strength. Journal of Preventive Medicine and Public Health 2015;49:35-44. doi: 10.3961/jpmph.15.055.
LX. Boettcher M, Machann J, Stefan N, Thamer C, Häring HU, Claussen CD, et al. Intermuscular adipose tissue (IMAT): association with other adipose tissue compartments and insulin sensitivity. J Magn Reson Imaging 2009 Jun;29(6):1340-5.
LXI. Navarrete-Reyes AP, Avila-Funes JA. Diabetes mellitus and the syndrome of frailty in the elderly. Rev Invest Clin 2010 Jul;62(4):327-32.
LXII. Ali S, García JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.Gerontology 2014;60(4):294-305.
LXIII. Nomura T, Ishiguro T, Ohira M, Ikeda Y. Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. J Diabetes Investig. 2018 Jan;9(1):186-92.
LXIV. Izzo A, Massimino E, Riccardi G, Della Pepa G. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients 2021 Jan 9;13(1). doi: 10.3390/nu13010183.
LXV. Gupta P, Aravindhan A, Gand ATL, Man REK, Fenwick EK, Mitchell P, et al. Association between the severity of diabetic retinopathy and falls in an Asian population with diabetes: The Singapore Epidemiology of Eye Diseases Study. JAMA Ophthalmol 2017 Dec 1;135(12):1410-6.
LXVI. Fukuda T, Bouchi R, Takeuchi T, Nakano Y, Murakami M, Minami I, et al. Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Res Care 2017 May 27;5(1):e000404.
LXVII. Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 2014 Sep;10(9):504-16.
LXVIII. Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo FC, et al. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrology Dialysis Transplantation 2015;30:1718-25. doi: 10.1093/ndt/gfv133.
LXIX. Ida S, Kaneko R, Nagata H, Noguchi Y, Araki Y, Nakai M, et al. Association between sarcopenia and sleep disorder in older patients with diabetes. Geriatr Gerontol Int 2019 May;19(5):399-403.
LXX. Murai J, Nishizawa H, Otsuka A, Fukuda S, Tanaka Y, Nagao H, et al. Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation. Cardiovasc Diabetol 2018 Aug 4;17(1):112.
LXXI. McDermott MM, Criqui MH, Greenland P, Guralnik JM, Liu K, Pearce WH, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. J Vasc Surg 2004 Mar;39(3):523-30.
LXXII. Dziubek W, Bulińska K, Stefańska M, Woźniewski M, Kropielnicka K, Jasiński T, et al. Peripheral arterial disease decreases muscle torque and functional walking capacity in elderly. Maturitas 2015;81:480-6. doi: 10.1016/j.maturitas.2015.06.001.
LXXIII. Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P. Diabetes and sarcopenic obesity: pathogenesis, diagnosis, and treatments. Frontiers in Endocrinology 2020;11. doi: 10.3389/fendo.2020.00568.
LXXIV. Scott D, Courten B, Ebeling PR. Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia’s ageing population? Medical Journal of Australia 2016;205: 329-33. doi: 10.5694/mja16.00446.
LXXV. Cui M, Gang X, Wang G, Xiao X, Li Z, Jiang Z, et al. A cross-sectional study. Medicine 2020;99: e18708. doi: 10.1097/md.0000000000018708.
LXXVI. Pinti MV, Fink GK, Hathaway QA, Durr AJ, Kunovac A, Hollander JM. Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. Am J Physiol Endocrinol Metab 2019 Feb 1;316(2):e268-85.
LXXVII. Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, et al. Sarcopenia: a time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):956-61.
LXXVIII. Garza-González EL, Gallegos-Flores EA, Gutiérrez JH, Flores-Monsivais JE, Nava González EJ. Biomarcadores moleculares en la predicción de sarcopenia. Revista de Salud Pública y Nutrición 2017;16: 23-32. doi: 10.29105/respyn16.1-4.
LXXIX. De Spiegeleer A, Beckwée D, Bautmans I, Petrovic M. Sarcopenia guidelines development group of the Belgian Society of Gerontology and Geriatrics (BSGG). Pharmacological interventions to improve muscle mass, muscle strength and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. Drugs Aging 2018 Aug;35(8):719-34.
LXXX. Garland H. Diabetic amyotrophy. BMJ 1955;2:1287-90. doi: 10.1136/bmj.2.4951.1287.
LXXXI. Dyck PJB, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle & Nerve 2002;25: 477-91. doi: 10.1002/mus.10080.
LXXXII. Pasnoor M, Dimachkie MM, Barohn RJ. Diabetic Neuropathy Part 2. Neurologic Clinics 2013;31:447-62. doi: 10.1016/j.ncl.2013.02.003.
LXXXIII. Garces-Sánchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck PJB. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus Neuropathy? Annals of Neurology 2011;69:1043-54. doi: 10.1002/ana.22334.
LXXXIV. Glenn MD, Jabari D. Diabetic lumbosacral radiculoplexus neuropathy (diabetic amyotrophy). Neurol Clin 2020 Aug;38(3):553-64.
LXXXV. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metabolism Research and Reviews 2011;27:620-8. doi: 10.1002/dmrr.1226.
LXXXVI. Llewelyn D, Gareth Llewelyn J. Diabetic amyotrophy: a painful radiculoplexus neuropathy. Practical Neurology 2019;19: 164-7. doi: 10.1136/practneurol-2018-002105.
LXXXVII. Laughlin RS, Dyck PJB. Electrodiagnostic testing in lumbosacral plexopathies. Physical Medicine and Rehabilitation Clinics of North America 2013;24:93-105. doi: 10.1016/j.pmr.2012.08.014.
LXXXVIII. Chan YC, Lo YL, Chan ESY. Immunotherapy for diabetic amyotrophy. Cochrane Database of Systematic Reviews. 2017. doi: 10.1002/14651858.cd006521.pub4.
LXXXIX. Nascimento FA, Gatto LAM, Lages RO, Neto HM, Demartini Z, Koppe GL. Diffuse idiopathic skeletal hyperostosis: A review. Surg Neurol Int 2014 Apr 16;5(Suppl 3):S122-5.
XC. Woon C. DISH (diffuse idiopathic skeletal hyperostosis). Ortho Bullets. Actualizado: 6/13/2021. Disponible en: https://www.orthobullets.com/.
XCI. Belanger TA, Rowe DE. Diffuse idiopathic skeletal hyperostosis: musculoskeletal manifestations. J Am Acad Orthop Surg 2001 Jul;9(4):258-67.
XCII. Hirasawa A, Wakao N, Kamiya M, Takeuchi M, Kawanami K, Murotani K, et al. The prevalence of diffuse idiopathic skeletal hyperostosis in Japan. The first report of measurement by CT and review of the literature. J Orthop Sci 2016 May;21(3):287-90.
XCIII. Mader R, Verlaan JJ, Buskila D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms. Nat Rev Rheumatol 2013 Dec;9(12):741-50.
XCIV. Kuperus JS, Mohamed Hoesein FA, de Jong PA, Verlaan JJ. Diffuse idiopathic skeletal hyperostosis: etiology and clinical relevance. Best Practice & Research Clinical Rheumatology 2020;34:101527. doi: 10.1016/j.berh.2020.101527.
XCV. Mader R, Pappone N, Baraliakos X, Eshed I, Sarzi-Puttini P, Atzeni F, et al. Diffuse idiopathic skeletal hyperostosis (DISH) and a possible inflammatory component. Current Rheumatology Reports 2021;23. doi: 10.1007/s11926-020-00972-x.
XCVI. Bakker JT, Kuperus JS, Kuijf HJ, Oner FC, de Jong PA, Verlaan JJ. Morphological characteristics of diffuse idiopathic skeletal hyperostosis in the cervical spine. PLoS One 2017 Nov 20;12(11):e0188414.
XCVII. Garber EK, Silver S. Pedal manifestations of DISH. Foot Ankle 1982 Jul;3(1):12-6.
XCVIII. Kuperus JS, Oudkerk SF, Foppen W, Mohamed Hoesein FA, Gielis WP, Waalwijk J, et al. Criteria for early-phase diffuse idiopathic skeletal hyperostosis: development and validation. Radiology 2019 May;291(2):420-6.
XCIX. Resnick D, Shaul SR, Robins JM. Diffuse idiopathic skeletal hyperostosis (DISH): Forestier’s disease with extraspinal manifestations. Radiology 1975 Jun;115(3):513-24.
C. Kuperus JS, Smit EJM, Pouran B, van Hamersvelt RW, van Stralen M, Seevinck PR, et al. Anterior longitudinal ligament in diffuse idiopathic skeletal hyperostosis: Ossified or displaced? Journal of Orthopaedic Research 2018;36:2491-6. Doi: 10.1002/jor.24020.
CI. Luo TD, Varacallo M. Diffuse idiopathic skeletal hyperostosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
CII. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17(1):1-45.
CIII. Weber DR, Haynes K, Leonard MB, Willi SM, Denburg MR. Type 1 diabetes is associated with an increased risk of fracture across the life span. A population-based cohort study using The Health Improvement Network (THIN). Diabetes Care 2015;38:1913-20. doi: 10.2337/dc15-0783.
CIV. Starup-Linde J, Hygum K, Harsløf T, Langdahl B. Type 1 diabetes and bone fragility: links and risks. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019;12:2539-47. doi: 10.2147/dmso.s191091.
CV. Weber DR, Schwartz G. Epidemiology of skeletal health in type 1 diabetes. Current Osteoporosis Reports 2016;14:327-36. doi: 10.1007/s11914-016-0333-0.
CVI. Halper-Stromberg E, Gallo T, Champakanath A, Taki I, Rewers M, Snell-Bergeon J, et al. Bone mineral density across the lifespan in patients with type 1 diabetes. J Clin Endocrinol Metab 2020 Mar 1;105(3). doi: 10.1210/clinem/dgz153.
CVII. Zhukouskaya VV, Eller-Vainicher C, Vadzianava VV, Shepelkevich AP, Zhurava IV, Korolenko GG, et al. Prevalence of morphometric vertebral fractures in patients with type 1 diabetes. Diabetes Care 2013 Jun;36(6):1635-40.
CVIII. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes. A meta-analysis. Osteoporosis International 2007;18: 427-44. doi: 10.1007/s00198-006-0253-4.
CIX. Pastor MMC, Campos Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo MD, García-Cervigón A. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporosis International 2000;11:455-9. doi: 10.1007/s001980070114.
CX. Romero-Díaz C, Duarte-Montero D, Gutiérrez-Romero SA, Mendivil CO. Diabetes and bone fragility. Diabetes Ther 2021 Jan;12(1):71-86.
CXI. Horcajada-Molteni MN, Chanteranne B, Lebecque P, Davicco MJ, Coxam V, Young A, et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. Journal of Bone and Mineral Research 2001;16:958-65. doi: 10.1359/jbmr.2001.16.5.958.
CXII. Kaur H, Joshee P, Franquemont S, Baumgartner A, Thurston J, Pyle L, et al. Bone mineral content and bone density is lower in adolescents with type 1 diabetes: A brief report from the RESISTANT and EMERALD studies. J Diabetes Complications 2018 Oct;32(10):931-3.
CXIII. Shah VN, Carpenter RD, Ferguson VL, Schwartz AV. Bone health in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2018 Aug;25(4):231-6.
CXIV. Palui R, Pramanik S, Mondal S, Ray S. Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus. World J Diabetes 2021 Jun 15;12(6):706-29.
CXV. Anastasilakis AD, Tsourdi E, Tabacco G, Naciu AM, Napoli N, Vescini F, et al. The impact of antiosteoporotic drugs on glucose metabolism and fracture risk in diabetes: good or bad news? J Clin Med Res 2021 Mar 2;10(5). doi: 10.3390/jcm10050996.
CXVI. Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D, Goulis DG. Type 2 diabetes and osteoporosis: a guide to optimal management. J Clin Endocrinol Metab 2017 Oct 1;102(10):3621-34.
CXVII. Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int 2018 Dec;29(12):2585-96.
CXVIII. Botella-Martínez S, Varo-Cenarruzabeitia N, Escalada San Martin J, Calleja-Canelas A. The diabetic paradox: Bone mineral density and fracture in type 2 diabetes. Endocrinol Nutr 2016 Nov;63(9):495-501.
CXIX. Sealand R, Razavi C, Adler RA. Diabetes mellitus and osteoporosis. Curr Diab Rep 2013 Jun;13(3):411-8.
CXX. Lecka-Czernik B. Diabetes, bone and glucose-lowering agents: basic biology. Diabetologia 2017 Jul;60(7):1163-9.
CXXI. Walsh JS, Vilaca T. Obesity, Type 2 diabetes and bone in adults. Calcified Tissue International 2017;100:528-35. doi: 10.1007/s00223-016-0229-0.
CXXII. Chandran M. Diabetes drug effects on the skeleton. Calcified Tissue International. 2017;100:133-49. doi: 10.1007/s00223-016-0203-x.
CXXIII. Ortiz-Lucas M, Hijazo-Larrosa S, Estébanez-De Miguel E. Capsulitis adhesiva del hombro: una revisión sistemática. Fisioter (Madr, Ed, impresa) 2010 Sep;32(5):229-35.
CXXIV. Whelton C, Peach CA. Review of diabetic frozen shoulder. Eur J Orthop Surg Traumatol 2018 Apr;28(3):363-71.
CXXV. Juel NG, Brox JI, Brunborg C, Holte KB, Berg TJ. Very high prevalence of frozen shoulder in patients with type 1 diabetes of ≥45 years’ duration: the Dialong Shoulder Study. Arch Phys Med Rehabil 2017 Aug;98(8):1551-9.
CXXVI. Chan JH, Ho BS, Alvi HM, Saltzman MD, Marra G. The relationship between the incidence of adhesive capsulitis and hemoglobin A. J Shoulder Elbow Surg 2017 Oct;26(10):1834-7.
CXXVII. Yian EH, Contreras R, Sodl JF. Effects of glycemic control on prevalence of diabetic frozen shoulder. J Bone Joint Surg Am 2012 May 16;94(10):919-23.
CXXVIII. Park HB, Gwark JY, Jung J. What serum lipid abnormalities are associated with adhesive capsulitis accompanied by diabetes? Clin Orthop Relat Res 2018 Nov;476(11):2231-7.
CXXIX. Lo SF, Chu SW, Muo CH, Meng NH, Chou LW, Huang WC, et al. Diabetes mellitus and accompanying hyperlipidemia are independent risk factors for adhesive capsulitis: a nationwide population-based cohort study (version 2). Rheumatol Int 2014 Jan;34(1):67-74.
CXXX. Alsubheen SA, Nazari G, Bobos P, MacDermid JC, Overend TJ, Faber K. Effectiveness of nonsurgical interventions for managing adhesive capsulitis in patients with diabetes: a systematic review. Arch Phys Med Rehabil 2019 Feb;100(2):350-65.
CXXXI. Mueller MJ, Sorensen CJ, McGill JB, Clark BR, Lang CE, Chen L, et al. Effect of a shoulder movement intervention on joint mobility, pain, and disability in people with diabetes: a randomized controlled trial. Phys Ther 2018 Sep 1;98(9):745-53.
CXXXII. Maund E, Craig D, Suekarran S, Neilson A, Wright K, Brealey S, et al. Management of frozen shoulder: a systematic review and cost-effectiveness analysis. Health Technol Assess 2012;16(11):1-264.
CXXXIII. Dehghan A, Pishgooei N, Salami MA, Zarch SMM, Nafisi-Moghadam R, Rahimpour S, et al. Comparison between NSAID and intra-articular corticosteroid injection in frozen shoulder of diabetic patients; a randomized clinical trial. Exp Clin Endocrinol Diabetes 2013 Feb;121(2):75-9.
CXXXIV. Akin-Takmaz S, Babaoglu G, Başar H, Baltacı B. Evaluation of the effects of intraarticular glucocorticoid injections on blood glucose levels in diabetes mellitus and nondiabetes mellitus patients with adhesive capsulitis of the shoulder. Niger J Clin Pract 2021 Feb;24(2):277-81.
CXXXV. Moon HJ, Choi KH, Lee SI, Lee OJ, Shin JW, Kim TW. Changes in blood glucose and cortisol levels after epidural or shoulder intra-articular glucocorticoid injections in diabetic or nondiabetic patients. Am J Phys Med Rehabil 2014 May;93(5):372-8.
CXXXVI. El Naggar TEDM, Maaty AIE, Mohamed AE. Effectiveness of radial extracorporeal shock-wave therapy versus ultrasound-guided low-dose intra-articular steroid injection in improving shoulder pain, function, and range of motion in diabetic patients with shoulder adhesive capsulitis. J Shoulder Elbow Surg 2020 Jul;29(7):1300-9.
CXXXVII. Yip M, Francis AM, Roberts T, Rokito A, Zuckerman JD, Virk MS. Treatment of adhesive capsulitis of the shoulder. JBJS Reviews 2018;6:e5-e5. doi: 10.2106/jbjs.rvw.17.00165
CXXXVIII. Harrison SR, Li D, Jeffery LE, Raza K, Hewison M. Vitamin D, autoimmune disease and rheumatoid arthritis. Calcif Tissue Int 2020 Jan;106(1):58-75.
CXXXIX. Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 2020 Jul;16(7):361-79.
CXL. Verma AK, Bhatt D, Goyal Y, Dev K, Beg MMA, Alsahli MA, et al. Association of rheumatoid arthritis with diabetic comorbidity: correlating accelerated insulin resistance to inflammatory responses in patients. J Multidiscip Healthc 2021 Apr 12;14:809-20.
CXLI. Ghosal S, Ghosal A. Diabetes and musculoskeletal disorders-a review. Journal of Diabetes, Metabolic Disorders & Control 2020;7:63-71. doi: 10.15406/jdmdc.2020.07.00202.
CXLII. Rehling T, Bjørkman ASD, Andersen MB, Ekholm O, Molsted S. Diabetes is associated with musculoskeletal pain, osteoarthritis, osteoporosis, and rheumatoid arthritis. J Diabetes Res 2019 Dec 6;2019:6324348.
CXLIII. Baghdadi LR. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: a systematic review and meta-analysis. PloS One 2020;15:e0235637. doi: 10.1371/journal.pone.0235637.
CXLIV. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One 2019 Jan 23;14(1):e0210459.
CXLV. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One 2019 Jan 23;14(1):e0210459.
CXLVI. Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Devel Ther 2019;13:57-70.
CXLVII. Ruscitti P, Masedu F, Alvaro S, Airò P, Battafarano N, Cantarini L, et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med 2019 Sep;16(9):e1002901.
CXLVIII. Gurzov EN, Stanley WJ, Pappas EG, Thomas HE, Gough DJ. The JAK/STAT pathway in obesity and diabetes. FEBS J 2016 Aug;283(16):3002-15.
CXLIX. Philippou E, Petersson SD, Rodomar C, Nikiphorou E. Rheumatoid arthritis and dietary interventions: systematic review of clinical trials. Nutr Rev 2021 Mar 9;79(4):410-28.
CL. Petersson S, Philippou E, Rodomar C, Nikiphorou E. The Mediterranean diet, fish oil supplements and Rheumatoid arthritis outcomes: evidence from clinical trials. Autoimmun Rev 2018 Nov;17(11):1105-14.
CLI. Mollard E, Michaud K. Mobile Apps for rheumatoid arthritis: opportunities and challenges. Rheum Dis Clin North Am 2019 May;45(2):197-209.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Diabetes
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
